

# Leishmania spp. proteome data sets: a comprehensive resource for vaccine development to target visceral leishmaniasis

Toni Aebischer \*

Agents of Mycoses, Parasitoses and Mycobacterioses, Robert Koch-Institut, Berlin, Germany

## Edited by:

Alexandre Barbosa Reis, Universidade Federal de Ouro Preto, Brazil

## Reviewed by:

William Castro-Borges, Universidade Federal de Ouro Preto, Brazil

Eduardo Ferraz Coelho, Universidade Federal de Minas Gerais, Brazil

## \*Correspondence:

Toni Aebischer, FG16 Erreger von Pilz- und Parasiteninfektionen und Mykobakteriosen, Robert Koch-Institut, Berlin 13353, Germany  
e-mail: [aebischera@rki.de](mailto:aebischera@rki.de)

Visceral leishmaniasis is a neglected infectious disease caused primarily by *Leishmania donovani* and *Leishmania infantum* protozoan parasites. A significant number of infections take a fatal course. Drug therapy is available but still costly and parasites resistant to first line drugs are observed. Despite many years of trial no commercial vaccine is available to date. However, development of a cost effective, needle-independent vaccine remains a high priority. Reverse vaccinology has attracted much attention since the term has been coined and the approach tested by Rappuoli and colleagues. This *in silico* selection of antigens from genomic and proteomic data sets was also adapted to aim at developing an anti-*Leishmania* vaccine. Here, an analysis of the efforts is attempted and the challenges to be overcome by these endeavors are discussed. Strategies that led to successful identification of antigens will be illustrated. Furthermore, these efforts are viewed in the context of anticipated modes of action of effective anti-*Leishmania* immune responses to highlight possible advantages and shortcomings.

**Keywords:** proteome, T cell antigen receptor, vaccine, kinetoplastida, major histocompatibility complex antigens

## INTRODUCTION

A cure or effective prophylaxis for visceral leishmaniasis (VL) also known as Kala azar is a prioritized objective in global efforts directed toward improving the situation for people at risk of and patients suffering from *Leishmania*-infections (1, 2). The problem of VL is grave as it is thought to be second only to malaria in terms of fatal infections (3). Therapy is one option to help the individual patient but on its own is unlikely to offer a lasting solution to manage the public health problem because of emerging resistance to available drugs (4). Vaccines are therefore considered a desirable, cost effective strategy complement (5).

There is encouraging evidence that vaccination against VL should be possible. Immunity is thought to depend on a protective cellular immune response requiring CD4 as well as CD8 T cells that activate leishmanicidal mechanisms in host phagocytes (6, 7) since their suppression correlates with disease (8, 9). Epidemiological data suggest that the majority of infections are in fact controlled and do not lead to disease. For example, the KalaNet study reported an estimate of only 1 in 10 infections leading to disease in India and Nepal where more than 50% of globally recorded fatal VL cases occur (10, 11). In addition, there is the paradigmatic example of lifelong protection against cutaneous leishmaniasis through the century old practice of Leishmanization. This deliberate infection of a non-immune person with virulent parasites (12) has been implemented in the immunization programs of soldiers of several armies in the Middle East but has been discontinued because of the risk of uncontrolled disease in a fraction of vaccines (13) and problems with vaccine strain stability (14). The protective efficacy against subsequent infection afforded by a healed primary infection due to Leishmanization in the majority of cases fostered

the development of attenuated live parasites (15–18) or parasites not pathogenic to humans (19) as vaccines also against VL. This approach works remarkably well in rodent models of disease and may be a very promising approach to control VL where this is fueled by a zoonotic cycle.

For human use, subunit vaccines based on selected parasite antigens, however, would offer a more defined and more stable alternative (20). But, major obstacles to their successful development exist and these are on the one hand the identification of the most effective antigens and on the other hand their formulation. Formulation relates to selecting adjuvants and/or delivery systems such as recombinant viruses (2, 21, 22) or bacteria (23, 24) and exploitation or engineering of immune-modulating agents and properties to induce protective antigen-specific CD4 and CD8 T cells. Although our understanding of what makes a protective response in humans remains sketchy (8, 9, 25), there is no reason to object to the idea that this can be achieved through vaccine formulation if selected *Leishmania*-antigens were fit for purpose.

In the post-genomic era, the approach to antigen selection and vaccine development has been revolutionized. The term reverse vaccinology has been coined by Rappuoli and colleagues (26) at the turn of the millennium to designate the process. The idea is simple and is about exploiting genomic and other -omics data sets to filter out relevant gene products *in silico*. Selection proceeds through an algorithm that is developed “backwards” starting from a known or anticipated mode of action of the vaccine. This has been impressively successful for the development of novel anti-Meningococcal Serotype B vaccines because (a) the mode of action was known and allowed to develop a straight forward *in vitro*

screening assay based on lysis-mediating antibodies and (b) this assay was scalable and had high throughput capacity (26, 27). The Reverse Vaccinology approach has also been adapted to identify potential vaccine protein antigens against leishmaniasis and the combined search terms “reverse vaccinology” and “*Leishmania*” retrieve five publications from PubMed as of March 10th 2014 (24, 28–32). Reverse Vaccinology when adapted to VL will aim at identifying vaccine antigens that induce protective CD4 and CD8 T cells (24, 28, 30).

In the following, I will try to critically assess the adaptation of the Reverse Vaccinology approach to the development of an anti-VL vaccine. However, before doing so, I will summarize in a bullet point way features of the cell biology of *Leishmania*-infection and of MHC class I and II dependent antigen-presentation in the context of this infection. The aim is to distil scenarios that allow identification of process-relevant steps through which reverse vaccinology may be improved. The reader will quickly note that this comes at a price. This is the deliberate simplification of our understanding of the parasite’s intracellular life style.

### BULLET POINT STYLE SUMMARY OF THE CELL BIOLOGY OF *LEISHMANIA* SPP. INFECTIONS

- Disease-causing *Leishmania* replicate in the form of amastigotes in a membrane-delimited intracellular habitat of host phagocytes (33).
- The habitat has the characteristics of a late endosome/early lysosome, i.e., a relatively low pH with numerous proteases such as cathepsins and other hydrolases present (34, 35).
- The parasites’ habitat is in communication with the host cell’s endocytic compartments via fusion and fission of vesicles (36, 37).
- Parasite protein secretion can occur via the classical, signal peptide-dependent pathways or, as recently favored, via the release of exosomes (38, 39).

### BULLET POINT STYLE SUMMARY OF ANTIGEN-PRESENTATION BY *LEISHMANIA*-INFECTED HOST CELLS

- Parasite proteins are processed for presentation by proteolysis inside vesicles and it is within a vesicular compartment that peptides form complexes with MHC class I and II histocompatibility antigens (37, 40).
- The so-called cross-presentation, i.e., formation of parasite peptide – MHC class I complexes does not involve proteasomal cleavage (41).
- Proteins secreted via the classical route or located on the surface of the parasite are more efficiently presented to stimulate CD4 and CD8 T cells (40, 42, 43).
- The major antigen-presenting cells initiating the immune response are dendritic cells (44, 45) while infected macrophages are likely the most frequent antigen-presenting cell during infection (46, 47).
- Macrophages need to be activated, e.g., through cytokines such as IFN- $\gamma$  to express MHC class II molecules, a prerequisite to present antigens to CD4 T cells (48, 49).
- Only a minority of infected macrophages seems to interact with *Leishmania*-specific T cells *in vivo* (46).

### BULLET POINT STYLE SUMMARY OF PROCESSES AND MOLECULE NUMBERS RELEVANT FOR ANTIGEN-PRESENTATION

- Mature dendritic cells express up to  $10^6$ – $10^7$  MHC Class II and  $10^5$  MHC I molecules per cell (50, 51).
- Mature dendritic cell “fix” a surface MHC class II-peptide complex repertoire to present an immunological snap shot to interacting T cells (52).
- Activated macrophages express  $10^5$ – $10^6$  MHC Class II and  $10^5$  MHC I molecules per cell and these are undergoing turn over and recycling (53).
- Immature dendritic cells and Macrophages constantly cycle MHC–peptide complexes from cell surface through endocytic peptide loading enabling compartments back to the surface allowing peptide sampling over time (54).
- Cells display two populations of MHC–peptide complexes, one with a fast off rate of the peptide ligand and one with slow off-rates, a property that in combination with dynamic sampling is a mechanism to enrich for the thermodynamically most stable MHC–peptide complexes for presentation (55).
- Estimates of the number of cognate MHC–peptide complexes required for successful T cell stimulations vary from a single complex (56) to several hundred (57) and a number in the order of  $10^2$  is a reasonable estimate (58).
- Amastigotes yield  $\sim 2$ – $4 \times 10^{-12}$  g of protein per cell that corresponds to  $3$ – $5 \times 10^7$  protein molecules per parasite assuming an average size of  $\sim 50$  kDa per molecule (40, 59).
- *Leishmania* genomes encode some 8200 distinct proteins (60), which are predicted to encode nearly  $3 \times 10^5$  MHC class I epitopes with binding capacity for MHC even when only a single MHC class I allele is considered (30).
- The average number of predicted epitopes per protein is thus  $>36$  hence  $>10^9$  epitope molecules are likely to be generated from a single parasite if all proteins were processed.
- Parasite proteins may become accessible for the presentation machinery either through parasite lysis, directed release (through exosomes or via classical secretion) or surface exposure and hydrolytic release.

### ALGORITHMS OF REVERSE VACCINOLOGY TO IDENTIFY CANDIDATE PROTEINS FOR ANTI-*LEISHMANIA* VACCINE DEVELOPMENT

The most puristic Reverse Vaccinology algorithms to identify candidate vaccine antigens adapted for leishmaniasis proceeded stepwise from genome to T cell epitope prediction (28, 30). For example, Herrera-Najera et al. (30) based their algorithm on the condition that a vaccine protects through induction of CD8 T cells recognizing a parasite protein-derived epitope in the context of MHC class I molecules. In a first step, they analyzed the complete genome for encoding peptides predicted to have MHC–ligand properties (for selected mouse H-2 class I alleles) using a sliding window of 8–11mer amino acids over the entire open reading frames and adapting a filter to account for proteasome-processing preferences implemented in the RankPep software. This identified  $\sim 3 \times 10^5$  candidate epitopes. To reduce this number, a stringent but arbitrary threshold of the binding score to MHC was introduced resulting in 250 candidate peptides. In step 2 of the process,

these candidates were further analyzed using different T cell epitope prediction algorithms. A set of 78 epitopes was predicted by all or nearly all software. In step 3, the 78 epitopes were compared to the predicted proteomes of putative hosts based on mouse and human genome data, the rationale being to reduce the risk of inducing autoimmune reactions. In this step, it was considered satisfactory that none of the selected peptide-epitopes had >80% identity with a host protein. However, there were peptides with lower identity, i.e., with up to 9 of 11 amino acids identical. Step 4 checked for conservation of the candidate protein containing the epitope(s) in different *Leishmania* spp. and other kinetoplastids. The authors noted that their algorithm did not identify any of the known, experimentally validated candidates. These failed the arbitrarily set stringent threshold for the MHC-binding score in step 1.

An alternative algorithm based on the same idea of vaccine mode of action was developed by John et al. (28). In this case, additional characteristics of a vaccine antigen were assumed and used for filtering. In step 1, subcellular localization was analyzed using PSORT and TMHMM software, respectively, and used to enrich for 903 proteins with predictions for plasma membrane localization or secretion and with counter-selection of proteins with more than one predicted transmembrane domain. This list was purged in step 2 of proteins showing homology to murine or human host proteins leaving 553 candidates in the basket. Selection step 3 analyzed the presence of MHC class I binding and step 4 of MHC class II binding peptides using several programs. Unfortunately, the adopted thresholds that reduced the number to 19 candidates were not described. This final set was tested again for similarity to host self-epitopes but this did not reduce the number further. As before, no experimentally identified protein antigen has passed this selection process.

While both of these approaches identified potentially immunogenic epitopes [in fact immunogenicity was demonstrated in the case of Ref. (30)], the fact that these algorithms did not identify any of the experimentally tested vaccine proteins/epitopes (which is not the same as the ideal vaccine antigen) is worrisome. What is missing?

### REFLECTIONS ON IMPROVING REVERSE VACCINOLOGY APPROACHES FOR THE PREDICTION OF CANDIDATE ANTIGENS FOR A VACCINE AGAINST LEISHMANIASIS

The working hypothesis that the success of a vaccine to prevent or treat VL in humans will rely on the induction of CD4 and CD8 T cells is valid. However, individual steps in the algorithms aiming at antigen identification need to be scrutinized on the one hand for the validity of underlying concepts and logic and on the other hand for their effectiveness as selecting filters. Since the above-mentioned studies offer recent examples, I shall follow steps as proposed in their algorithms for illustration.

Herrera-Najera et al. (30) started with predicting MHC-binding peptides considering the proteasomal pathway of peptide generation. While there is evidence against involvement of the proteasome for cross-presentation of parasite-delivered antigens (41), there is currently no evidence in support of it. Thus, this filter may neither be necessary nor instructive. MHC-binding peptide prediction highlighted nearly  $3 \times 10^5$  candidates. Thus, every ORF is

likely to encode more than one candidate hence the filter lacks efficiency. An arbitrary threshold as introduced can seemingly provide filtering capacity but will quickly become too stringent since in the said example it excluded all experimentally identified candidates. The next step involved selection based on T cell epitope predicting algorithms. This filtering is highly error prone and probably superfluous as the T cell receptor is an explorative, adaptive molecule that can recognize epitope variants (61). Because of this, the advantage of implementing this step can be questioned. In addition, there is little evidence from many other areas of its predicting power.

Both *in silico* Reverse Vaccinology algorithms discussed added then an additional step of counter-selection at the epitope stage by testing for molecular mimicry of proteins of putative host species. In theory, this is totally reasonable. In practice, this is either insensitive [see Ref. (30)] or seems impossible since cognate interaction of MHC-peptide complexes with TCRs is not as specific as previously thought and, where analyzed, the sequence space allowing mimicry is extensive (62). The intricacies of this have been reviewed recently in the context of cancer-cell specific epitopes and provide instructive insight (63). In conclusion, T cell epitope prediction may have no and selection against host proteins very limited practical value.

Does this mean that genome and other genomics information offers no opportunities of adapting the Reverse Vaccinology approach to our field? This view may be too pessimistic. The algorithm proposed by John et al. (28) enriched for proteins predicted to be secreted or surface localized. Reasons for this are that these two topologies will facilitate access for the MHC processing and loading machineries from living, actively replicating parasites. This assumption is founded on experimental evidence since phagocytes infected with parasites genetically engineered to secrete or surface expose trackable antigens were more readily presenting the antigens (40, 42). However, evidence that this situation is the prevailing or most relevant mode of antigen-delivery for presentation *in vivo* is still scarce. In fact recent data from *in vivo* tracing approaches suggest that control of infection and healing involves engagement of only a minority of infected or parasite-exposed cells with protective T cells (47, 64). Also, there is evidence that major normally secreted antigens are relatively resistant to proteolytic processing, as shown for the highly abundant secreted proteophosphoglycans of *Leishmania mexicana* (65). This is probably no surprise since parasite products secreted into the phagolysosomal compartment should have evolved this property to preserve their function. Nonetheless, under the assumption that a productively infected cell is the most relevant antigen-presenting cell in these infections, filtering candidate antigens for secreted or surface exposed localization remains reasonable.


Alternative scenarios of antigen-presentation that should be considered are host cells that become activated under pro-inflammatory conditions to kill the parasites or cells in which a fraction of parasites may undergo spontaneous lysis, e.g., due to faulty replication. In these cases, the entire set of parasite proteins will ultimately become available for processing and presentation. Of note, from the point of view, which set of proteins will be presented these modes are also akin to a scenario where antigens reach the processing machinery via the recently proposed secretion pathway involving exosome release by live parasite. Antigens

accessible to the processing machinery in these situations are similar because the proteome of exosomes largely overlaps that of the abundant protein set present in whole parasite lysates [e.g., compare data from Ref. (39, 66)].

In all these situations, I would argue that relative protein abundance is the single most important parameter for candidate antigen selection and is of a high practical value. The algorithms discussed so far did not take relative protein abundance into account. Instead they assumed equivalence of all predicted proteins with respect to their chance to being successfully processed and loaded onto MHC molecules. Not having considered abundance may be an additional reason why none of the experimentally identified candidate antigens were within the set identified by purely bioinformatics approaches. Fortunately proteome data sets reporting about relative abundance of proteins are available and these resources are permanently expanding (67–73) although improvements to the reporting of quantitative aspects of proteome data would be desirable.

In the following, I would like to analyze the potential of integrating quantitative proteome information with a quantitative view of the presentation process (see also bullet point style summaries above) into an algorithm of Reverse Vaccinology. If we accept that in principle each parasite protein contains functional MHC I and II binding peptides and, thus, potential T cell epitopes, we may simply base our estimates on the number of protein molecules per parasite ( $\sim 5 \times 10^7$  molecules). Similarly, if we agree that both CD4 and CD8 cells are relevant for protection, we can base our analysis on the number of MHC class I molecules expressed per antigen-presenting cell ( $\sim 10^5$  molecules) since this is thought to be lower than the number of class II molecules, hence can be considered the limiting peptide receptor species. To illustrate the next steps, I will base my arguments on a data set published by our group. We aimed at identifying the relative abundance of proteins in amastigotes of *L. mexicana* based on a label free method that deduces a protein abundance index (emPAI) for each protein in a data set (66, 74). The reason for this choice is simply that equivalent data is not easily accessible in other comparable proteome data sets. When parasite proteins are ranked according to their emPAI value, it is quickly realized that proteins encoded by less than 50 and 200 genes contribute more than 25 and 50% of the total parasite protein content in terms of mass (Figure 1).


These relative values can be expressed as number of molecules per parasite taking into consideration the respective molecular weight and the total protein content per parasite ( $\sim 4$  pg). Thus, the copy number per cell of proteins detected in current proteomic analyses ranges from a few million to a couple of 100 molecules. MHC–peptide complex formation, however, ultimately follows the law of mass, hence abundant molecules have a greater chance of becoming processed and ensuing peptides bound to the MHC-binding groove. The simplest version of predicting the chance of a protein to be successful in this respect is to calculate an expected value for how often this may be the case if  $10^5$  MHC molecules are allowed to dip into the compartment where the peptides are formed and pick a peptide (remember as a further simplification, we equal 1 protein to 1 epitope). The expected value of MHC–peptide complexes for each protein in the data set can be plotted in an ordered way according to protein abundance, which produces



**FIGURE 1 | Relative contribution of individual proteins to total protein content of *Leishmania* amastigotes.** For illustration, the contribution of each of 1764 proteins detected by shot gun proteomics in *L. mexicana* amastigotes (66) is expressed as percent to total protein mass and values plotted in ordered fashion for each protein. Numbers on X-axes show the rank of the *n*th protein at the thresholds of 75, 50, and 25% of total mass.

an S-shaped curve (Figure 2). For candidate prediction purposes, it is then necessary to try to define rationally a threshold below which the chance of a peptide species to be bound by a stimulatory number of MHC molecules becomes negligible. One way to set this threshold is to adopt the number of surface MHC–epitope complexes required for stimulating T cells as defined by immunologists. As mentioned before a reasonable estimate for this is in the order of 100 complexes, which is indicated by a horizontal line in Figure 2. The expected number of MHC–peptides was calculated for experimentally validated, naturally immunogenic proteins and, indeed, for the majority the expected number is above this threshold (Figure 2; green shaded area of plot). A complementary way to define the threshold is by extrapolation of experimental data on individual parasite proteins that were assayed either in vaccination studies or in T cell stimulation tests. Importantly, there is experimental evidence for a lower boundary of the protein copy number per cell value at which infected macrophages do no longer stimulate the respective antigen-specific CD4 T cells (40). This threshold is indicated as a blue dotted line in Figure 2.

The presented approach is easily expanded or adapted to additional proteomic data sets when information on relative protein abundance becomes available. It reveals not only the likely reason why most experimentally studied antigens were immuno- and antigenic but also defines a large number of additional candidates. In contrast, the majority of the candidates predicted purely by bioinformatics (28, 30) were not in the proteome data set. This may indeed indicate that their respective copy number per parasite was below detection levels of the method (which is then likely to be also below the detection level of the MHC presentation machinery). However, this conclusion has to be drawn with caution as the likelihood of detecting the protein by proteomics can be reduced



bioinformatically accessible factor to improve the algorithm. It has been shown that kinetic stability of MHC-peptide complexes is probably the single most important determinant that defines immunodominant T cell epitopes (75). Furthermore, dynamic exchange of weakly binding peptides for more stably bound peptides has been shown to occur upon MHC-peptide recycling from and to the plasma membrane (76). Thus, in theory the algorithm for ranking candidates may include a weighting factor based on predicted peptide off-rates from their MHC receptors. This factor may be multiplied by protein/peptide abundance to derive an "effective concentration" of a particular peptide. A high effective concentration may be the reason underlying the efficacy of leishmanial  $\gamma$ -glutamylcysteine synthetase as an effective vaccine in animal models of *Leishmania donovani* infection (77, 78). Alternatively, this antigen may be more abundantly expressed in *L. donovani* than suggested by the data derived from *L. mexicana* that were used here for illustration. Consistent with the latter idea, the same  $\gamma$ -glutamylcysteine synthetase-based vaccines were less effective against *L. mexicana* (79). Unfortunately, experimental data on an exemplary set of antigens to derive such a weighting factor are lacking and given the uncertainties associated with MHC-peptide ligand predicting algorithms the practical value of such a factor is currently difficult to assess.

## ACKNOWLEDGMENTS

This work was supported by grant Ae16/5-1 to Toni Aebischer from the Deutsche Forschungsgemeinschaft within the Priority program SPP1580.

## REFERENCES

1. Singh B, Sundar S. Leishmaniasis: vaccine candidates and perspectives. *Vaccine* (2012) **30**(26):3834–42. doi:10.1016/j.vaccine.2012.03.068
2. Kedzierski L. Leishmaniasis vaccine: where are we today? *J Glob Infect Dis* (2010) **2**(2):177–85. doi:10.4103/0974-777X.62881
3. Mather CD, Ezzati M, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. *PLoS Negl Trop Dis* (2007) **1**(2):e114. doi:10.1371/journal.pntd.0000114
4. Oliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done



- in India, 1980–2004. *Lancet Infect Dis* (2005) 5(12):763–74. doi:10.1016/S1473-3099(05)70296-6
5. Lee BY, Bacon KM, Shah M, Kitchen SB, Connor DL, Slayton RB. The economic value of a visceral leishmaniasis vaccine in Bihar state, India. *Am J Trop Med Hyg* (2012) 86(3):417–25. doi:10.4269/ajtmh.2012.10-0415
  6. Fernandes AP, Coelho EA, Machado-Coelho GL, Grimaldi GJ, Gazzinelli RT. Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives. *Curr Opin Microbiol* (2012) 15(4):476–85. doi:10.1016/j.mib.2012.05.002
  7. Belkaid Y, Von SE, Mendez S, Lira R, Caler E, Bertholet S, et al. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intra-dermal challenge with *Leishmania major*. *J Immunol* (2002) 168(8):3992–4000. doi:10.4049/jimmunol.168.8.3992
  8. Gautam S, Kumar R, Singh N, Singh AK, Rai M, Sacks D, et al. CD8 T cell exhaustion in human visceral leishmaniasis. *J Infect Dis* (2014) 209(2):290–9. doi:10.1093/infdis/jit401
  9. Nylén S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, Sacks D. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4<sup>+</sup>CD25<sup>+</sup> (Foxp3) regulatory T cells in human visceral leishmaniasis. *J Exp Med* (2007) 204(4):805–17. doi:10.1084/jem.20061141
  10. Stauch A, Sarkar RR, Picado A, Ostyn B, Sundar S, Rijal S, et al. Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. *PLoS Negl Trop Dis* (2011) 5(11):e1405. doi:10.1371/journal.pntd.0001405
  11. Ostyn B, Gidwani K, Khanal B, Picado A, Chappuis F, Singh SP, et al. Incidence of symptomatic and asymptomatic *Leishmania donovani* infections in high-endemic foci in India and Nepal: a prospective study. *PLoS Negl Trop Dis* (2011) 5(10):e1284. doi:10.1371/journal.pntd.0001284
  12. Nadim A, Javadian E, Tahvildar-Bidruni G, Ghorbani M. Effectiveness of leishmanization in the control of cutaneous leishmaniasis. *Bull Soc Pathol Exot Filiales* (1983) 76(4):377–83.
  13. Hosseini SM, Hatam GR, Ardehali S. Characterization of *Leishmania* isolated from unhealed lesions caused by leishmanization. *East Mediterr Health J* (2005) 11(1–2):240–3.
  14. Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, Noazin S, et al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. *Vaccine* (2005) 23(28):3642–8. doi:10.1016/j.vaccine.2005.02.015
  15. Dey R, Dagur PK, Selvapandian A, McCoy JP, Salotra P, Duncan R, et al. Live attenuated *Leishmania donovani* p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice. *J Immunol* (2013) 190(5):2138–49. doi:10.4049/jimmunol.1202801
  16. Spath GF, Lye LF, Segawa H, Turco SJ, Beverley SM. Identification of a compensatory mutant (lpg2-REV) of *Leishmania major* able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies. *Infect Immun* (2004) 72(6):3622–7. doi:10.1128/IAI.72.6.3622-3627.2004
  17. Titus RG, Gueiros-Filho FJ, de Freitas LA, Beverley SM. Development of a safe live *Leishmania* vaccine line by gene replacement. *Proc Natl Acad Sci U S A* (1995) 92(22):10267–71. doi:10.1073/pnas.92.22.10267
  18. Fiuza JA, Santiago Hda C, Selvapandian A, Gannavaram S, Ricci ND, Bueno LL, et al. Induction of immunogenicity by live attenuated *Leishmania donovani* centrin deleted parasites in dogs. *Vaccine* (2013) 31(14):1785–92. doi:10.1016/j.vaccine.2013.01.048
  19. Saljoughian N, Taheri T, Rafati S. Live vaccination tactics: possible approaches for controlling visceral leishmaniasis. *Front Immunol* (2014) 5:134. doi:10.3389/fimmu.2014.00134
  20. Coler RN, Reed SG. Second-generation vaccines against leishmaniasis. *Trends Parasitol* (2005) 21(5):244–9. doi:10.1016/j.pt.2005.03.006
  21. Darrah PA, Hegde ST, Patel DT, Lindsay RW, Chen L, Roederer M, et al. IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. *J Exp Med* (2010) 207(7):1421–33. doi:10.1084/jem.20092532
  22. Maroof A, Brown N, Smith B, Hodgkinson MR, Maxwell A, Losch FO, et al. Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis. *J Infect Dis* (2012) 205(5):853–63. doi:10.1093/infdis/jir842
  23. Yang DM, Fairweather N, Button LL, McMaster WR, Kahl LP, Liew FY. Oral *Salmonella typhimurium* (AroA–) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. *J Immunol* (1990) 145(7):2281–5.
  24. Schroeder J, Aebischer T. Vaccines for leishmaniasis: from proteome to vaccine candidates. *Hum Vaccin* (2011) 7:doi:10.4161/hv.7.0.14556
  25. Singh OP, Gidwani K, Kumar R, Nylén S, Jones SL, Boelaert M, et al. Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. *Clin Vaccine Immunol* (2012) 19(6):961–6. doi:10.1128/CVI.00143-12
  26. Rappuoli R. Reverse vaccinology. *Curr Opin Microbiol* (2000) 3(5):445–50. doi:10.1016/S1369-5274(00)00119-3
  27. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. *Science* (2000) 287(5459):1816–20. doi:10.1126/science.287.5459.1816
  28. John L, John GJ, Kholia T. A reverse vaccinology approach for the identification of potential vaccine candidates from *Leishmania* spp. *Appl Biochem Biotechnol* (2012) 167(5):1340–50. doi:10.1007/s12010-012-9649-0
  29. Resende DM, Rezende AM, Oliveira NJ, Batista IC, Correa-Oliveira R, Reis AB, et al. An assessment on epitope prediction methods for protozoa genomes. *BMC Bioinformatics* (2012) 13:309. doi:10.1186/1471-2105-13-309
  30. Herrera-Najera C, Pina-Aguilar R, Xacur-García F, Ramirez-Sierra MJ, Dumon-Teil E. Mining the *Leishmania* genome for novel antigens and vaccine candidates. *Proteomics* (2009) 9(5):1293–301. doi:10.1002/pmic.200800533
  31. Ouakad M, Bahi-Jaber N, Chenik M, Dellagi K, Louzir H. Selection of endogenous reference genes for gene expression analysis in *Leishmania major* developmental stages. *Parasitol Res* (2007) 101(2):473–7. doi:10.1007/s00436-007-0491-1
  32. Ben-Othman R, Guizani-Tabbane L, Dellagi K. *Leishmania* initially activates but subsequently down-regulates intracellular mitogen-activated protein kinases and nuclear factor-kappaB signaling in macrophages. *Mol Immunol* (2008) 45(11):3222–9. doi:10.1016/j.molimm.2008.02.019
  33. Antoine JC, Prina E, Jouanne C, Bongrand P. Parasitophorous vacuoles of *Leishmania amazonensis*-infected macrophages maintain an acidic pH. *Infect Immun* (1990) 58(3):779–87.
  34. Courret N, Frehel C, Gouhier N, Pouchelet M, Prina E, Roux P, et al. Biogenesis of *Leishmania*-harbouring parasitophorous vacuoles following phagocytosis of the metacyclic promastigote or amastigote stages of the parasites. *J Cell Sci* (2002) 115:2303–16.
  35. Burchmore RJ, Barrett MP. Life in vacuoles – nutrient acquisition by *Leishmania* amastigotes. *Int J Parasitol* (2001) 31(12):1311–20. doi:10.1016/S0020-7519(01)00259-4
  36. Collins HL, Schaible UE, Ernst JD, Russell DG. Transfer of phagocytosed particles to the parasitophorous vacuole of *Leishmania mexicana* is a transient phenomenon preceding the acquisition of annexin I by the phagosome. *J Cell Sci* (1997) 110(Pt 2):191–200.
  37. Muraile E, Cazareth J, Gounon P, Hoebeke J, Lippuner C, Soares H, et al. Visualization of peptide/MHC complexes at the surface and in the intracellular compartments of cells infected in vivo by *Leishmania major*. *PLoS Pathog* (2010) 6(10):e1001154. doi:10.1371/journal.ppat.1001154
  38. Lambert U, Silverman JM, Nandan D, McMaster WR, Clos J, Foster LJ, et al. Secreted virulence factors and immune evasion in visceral leishmaniasis. *J Leukoc Biol* (2012) 91(6):887–99. doi:10.1189/jlb.0611326
  39. Silverman JM, Clos J, Horakova E, Wang AY, Wiesgigl M, Kelly I, et al. *Leishmania* exosomes modulate innate and adaptive immune responses through effects on monocytes and dendritic cells. *J Immunol* (2010) 185(9):5011–22. doi:10.4049/jimmunol.1000541
  40. Wolfram M, Fuchs M, Wiese M, Stierhof YD, Overath P. Antigen presentation by *Leishmania mexicana*-infected macrophages: activation of helper T cells by a model parasite antigen secreted into the parasitophorous vacuole or expressed on the amastigote surface. *Eur J Immunol* (1996) 26(12):3153–62. doi:10.1002/eji.1830261248
  41. Bertholet S, Goldszmid R, Morrot A, Debrabant A, Afrin F, Collazo-Custodio C, et al. *Leishmania* antigens are presented to CD8+ T cells by a transporter associated with antigen processing-independent pathway in vitro and in vivo. *J Immunol* (2006) 177(6):3525–33. doi:10.4049/jimmunol.177.6.3525
  42. Prickett S, Gray PM, Colpitts SL, Scott P, Kaye PM, Smith DF. In vivo recognition of ovalbumin expressed by transgenic *Leishmania* is determined by

- its subcellular localization. *J Immunol* (2006) **176**(8):4826–33. doi:10.4049/jimmunol.176.8.4826
43. Bertholet S, Debrabant A, Afrin F, Caler E, Mendez S, Tabbara KS, et al. Antigen requirements for efficient priming of CD8+ T cells by *Leishmania major*-infected dendritic cells. *Infect Immun* (2005) **73**(10):6620–8. doi:10.1128/IAI.73.10.6620-6628.2005
  44. Misslitz AC, Bonhagen K, Harbecke D, Lippuner C, Kamradt T, Aebischer T. Two waves of antigen-containing dendritic cells in vivo in experimental *Leishmania major* infection. *Eur J Immunol* (2004) **34**(3):715–25. doi:10.1002/eji.200324391
  45. Schmid M, Wege AK, Ritter U. Characteristics of “Tip-DCs and MDSCs” and their potential role in leishmaniasis. *Front Microbiol* (2012) **3**:74. doi:10.3389/fmicb.2012.00074
  46. Filipe-Santos O, Pescher P, Breart B, Lippuner C, Aebischer T, Glaichenhaus N, et al. A dynamic map of antigen recognition by CD4 T cells at the site of *Leishmania major* infection. *Cell Host Microbe* (2009) **6**(1):23–33. doi:10.1016/j.chom.2009.04.014
  47. Muller AJ, Filipe-Santos O, Eberl G, Aebischer T, Spath GF, Bousso P. CD4+ T cells rely on a cytokine gradient to control intracellular pathogens beyond sites of antigen presentation. *Immunity* (2012) **37**(1):147–57. doi:10.1016/j.immuni.2012.05.015
  48. Wolfram M, Ilg T, Mottram JC, Overath P. Antigen presentation by *Leishmania mexicana*-infected macrophages: activation of helper T cells specific for amastigote cysteine proteinases requires intracellular killing of the parasites. *Eur J Immunol* (1995) **25**(4):1094–100. doi:10.1002/eji.1830250435
  49. Courret N, Prina E, Mougneau E, Saraiva EM, Sacks DL, Glaichenhaus N, et al. Presentation of the *Leishmania* antigen LACK by infected macrophages is dependent upon the virulence of the phagocytosed parasites. *Eur J Immunol* (1999) **29**(3):762–73. doi:10.1002/(SICI)1521-4141(199903)29:03<762::AID-IMMU762>3.0.CO;2-4
  50. Inaba K, Turley S, Iyoda T, Yamaide F, Shimoyama S, Reis e Sousa C, et al. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. *J Exp Med* (2000) **191**(6):927–36. doi:10.1084/jem.191.6.927
  51. Santambrogio L, Sato AK, Fischer FR, Dorf ME, Stern LJ. Abundant empty class II MHC molecules on the surface of immature dendritic cells. *Proc Natl Acad Sci U S A* (1999) **96**(26):15050–5. doi:10.1073/pnas.96.26.15050
  52. Pierre P, Turley SJ, Gatti E, Hull M, Meltzer J, Mirza A, et al. Developmental regulation of MHC class II transport in mouse dendritic cells. *Nature* (1997) **388**(6644):787–92. doi:10.1038/42039
  53. Yewdell JW, Reits E, Neefjes J. Making sense of mass destruction: quantitating MHC class I antigen presentation. *Nat Rev Immunol* (2003) **3**(12):952–61. doi:10.1038/nri1250
  54. Delamarre L, Holcombe H, Mellman I. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. *J Exp Med* (2003) **198**(1):111–22. doi:10.1084/jem.20021542
  55. Su RC, Miller RG. Stability of surface H-2K(b), H-2D(b), and peptide-receptive H-2K(b) on splenocytes. *J Immunol* (2001) **167**(9):4869–77. doi:10.4049/jimmunol.167.9.4869
  56. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. *Immunity* (1996) **4**(6):565–71. doi:10.1016/S1074-7613(00)80483-5
  57. Kimachi K, Croft M, Grey HM. The minimal number of antigen-major histocompatibility complex class II complexes required for activation of naive and primed T cells. *Eur J Immunol* (1997) **27**(12):3310–7. doi:10.1002/eji.1830271230
  58. Manz BN, Jackson BL, Petit RS, Dustin ML, Groves J. T-cell triggering thresholds are modulated by the number of antigen within individual T-cell receptor clusters. *Proc Natl Acad Sci U S A* (2011) **108**(22):9089–94. doi:10.1073/pnas.1018771108
  59. Overath P, Aebischer T. Antigen presentation by macrophages harboring intravesicular pathogens. *Parasitol Today* (1999) **15**(8):325–32. doi:10.1016/S0169-4758(99)01473-8
  60. Ivens AC, Peacock CS, Worthey EA, Murphy L, Aggarwal G, Berriman M, et al. The genome of the kinetoplastid parasite, *Leishmania major*. *Science* (2005) **309**(5733):436–42. doi:10.1126/science.1112680
  61. Newell EW, Ely LK, Kruse AC, Reay PA, Rodriguez SN, Lin AE, et al. Structural basis of specificity and cross-reactivity in T cell receptors specific for cytochrome c-I-E(k). *J Immunol* (2011) **186**(10):5823–32. doi:10.4049/jimmunol.1100197
  62. Sharav T, Wiesmuller KH, Walden P. Mimotope vaccines for cancer immunotherapy. *Vaccine* (2007) **25**(16):3032–7. doi:10.1016/j.vaccine.2007.01.033
  63. Hastings KT. GILT: shaping the MHC class II-restricted peptidome and CD4 T cell-mediated immunity. *Front Immunol* (2013) **4**:429. doi:10.3389/fimmu.2013.00429
  64. Olekhovitch R, Ryffel B, Muller AJ, Bousso P. Collective nitric oxide production provides tissue-wide immunity during *Leishmania* infection. *J Clin Invest* (2014) **124**(4):1711–22. doi:10.1172/JCI72058
  65. Aebischer T, Harbecke D, Ilg T. Proteophosphoglycan, a major secreted product of intracellular *Leishmania mexicana* amastigotes, is a poor B-cell antigen and does not elicit a specific conventional CD4+ T-cell response. *Infect Immun* (1999) **67**(10):5379–85.
  66. Paape D, Barrios-Llerena ME, Le BT, Mackay L, Aebischer T. Gel free analysis of the proteome of intracellular *Leishmania mexicana*. *Mol Biochem Parasitol* (2010) **169**(2):108–14. doi:10.1016/j.molbiopara.2009.10.009
  67. Nirujogi RS, Pawar H, Renuse S, Kumar P, Chavan S, Sathe G, et al. Moving from unsequenced to sequenced genome: reanalysis of the proteome of *Leishmania donovani*. *J Proteomics* (2014) **97**:48–61. doi:10.1016/j.jprot.2013.04.021
  68. Pescher P, Blisnick T, Bastin P, Spath GF. Quantitative proteome profiling informs on phenotypic traits that adapt *Leishmania donovani* for axenic and intracellular proliferation. *Cell Microbiol* (2011) **13**(7):978–91. doi:10.1111/j.1462-5822.2011.01593.x
  69. Paape D, Aebischer T. Contribution of proteomics of *Leishmania* spp. to the understanding of differentiation, drug resistance mechanisms, vaccine and drug development. *J Proteomics* (2011) **74**(9):1614–24. doi:10.1016/j.jprot.2011.05.005
  70. Sardar AH, Kumar S, Kumar A, Purkait B, Das S, Sen A, et al. Proteome changes associated with *Leishmania donovani* promastigote adaptation to oxidative and nitrosative stresses. *J Proteomics* (2013) **81**:185–99. doi:10.1016/j.jprot.2013.01.011
  71. Biyani N, Madhubala R. Quantitative proteomic profiling of the promastigotes and the intracellular amastigotes of *Leishmania donovani* isolates identifies novel proteins having a role in *Leishmania* differentiation and intracellular survival. *Biochim Biophys Acta* (2012) **1824**(12):1342–50. doi:10.1016/j.bbapap.2012.07.010
  72. Singh AK, Roberts S, Ullman B, Madhubala R. A quantitative proteomic screen to identify potential drug resistance mechanism in alpha-difluoromethylornithine (DFMO) resistant *Leishmania donovani*. *J Proteomics* (2014) **102**:44–59. doi:10.1016/j.jprot.2014.02.030
  73. Santarem N, Racine G, Silvestre R, Cordeiro-da-Silva A, Ouellette M. Exoproteome dynamics in *Leishmania infantum*. *J Proteomics* (2013) **84**:106–18. doi:10.1016/j.jprot.2013.03.012
  74. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. *Mol Cell Proteomics* (2005) **4**(9):1265–72. doi:10.1074/mcp.M500061-MCP200
  75. Lazarski CA, Chaves FA, Jenks SA, Wu S, Richards KA, Weaver JM, et al. The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. *Immunity* (2005) **23**(1):29–40. doi:10.1016/j.immuni.2005.05.009
  76. Sijts AJ, Pamer EG. Enhanced intracellular dissociation of major histocompatibility complex class I-associated peptides: a mechanism for optimizing the spectrum of cell surface-presented cytotoxic T lymphocyte epitopes. *J Exp Med* (1997) **185**(8):1403–11. doi:10.1084/jem.185.8.1403
  77. Carter KC, Henriquez FL, Campbell SA, Roberts CW, Nok A, Mullen AB, et al. DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against *Leishmania donovani* infection. *Vaccine* (2007) **25**(2):4502–9. doi:10.1016/j.vaccine.2007.03.014
  78. Henriquez FL, Campbell SA, Roberts CW, Mullen AB, Burchmore R, Carter KC. Vaccination with recombinant *Leishmania donovani* gamma-glutamylcysteine

- synthetase fusion protein protects against *L. donovani* infection. *J Parasitol* (2010) **96**(5):929–36. doi:10.1645/GE-2360.1
79. Campbell SA, Alawa J, Doro B, Henriquez FL, Roberts CW, Nok A, et al. Comparative assessment of a DNA and protein *Leishmania donovani* gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by *L. major* or *L. mexicana* infection. *Vaccine* (2012) **30**(7):1357–63. doi:10.1016/j.vaccine.2011.12.067
80. Julia V, McSorley SS, Malherbe L, Breittmayer JP, Girard-Pipau F, Beck A, et al. Priming by microbial antigens from the intestinal flora determines the ability of CD4+ T cells to rapidly secrete IL-4 in BALB/c mice infected with *Leishmania major*. *J Immunol* (2000) **165**(10):5637–45. doi:10.4049/jimmunol.165.10.5637
81. Schroeder J, Brown N, Kaye P, Aebischer T. Single dose novel *Salmonella* vaccine enhances resistance against visceralizing *L. major* and *L. donovani* infection in susceptible BALB/c mice. *PLoS Negl Trop Dis* (2011) **5**(12):e1406. doi:10.1371/journal.pntd.0001406

**Conflict of Interest Statement:** The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 15 March 2014; accepted: 19 May 2014; published online: 10 June 2014.

Citation: Aebischer T (2014) *Leishmania* spp. proteome data sets: a comprehensive resource for vaccine development to target visceral leishmaniasis. *Front. Immunol.* **5**:260. doi: 10.3389/fimmu.2014.00260

This article was submitted to *Immunotherapies and Vaccines*, a section of the journal *Frontiers in Immunology*.

Copyright © 2014 Aebischer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.